|
Home /
About Watson Pharmaceuticals
Watson Pharmaceuticals
 Watson Pharmaceuticals
Watson Pharmaceuticals, Inc. is a leading
specialty pharmaceutical company that uses innovative science and market
insight to develop responsive pharmaceutical products for a changing world.
Since its founding in 1984, Watson has pursued a growth strategy combining
internal product development, strategic alliances and collaborations, and
synergistic acquisitions of products and businesses. Watson Pharmaceuticals is
uniquely positioned with its infrastructure and internal research and
development capabilities to support a leading generic business and a growing
brand business.
Watson Pharmaceuticals - focus
Watson Pharmaceuticals, Inc. (NYSE: WPI),
headquartered in Corona, California, is engaged in the development,
manufacture, sale and distribution of proprietary (brand) and off-patent
(generic) pharmaceutical products.
Watson Pharmaceuticals pursues a
strategy of generating revenue through established brand and generic
businesses, capitalizing on the Company's proven ability to support the
development and commercialization of a broad range of brand and generic
pharmaceutical products.
A diversified, specialty pharmaceutical
company, Watson markets its products through three core areas: specialty
products, Nephrology and generic products. These are areas where the Company
has established strengths, reach and expertise. Approximately 75% of Watson
revenue is comprised of generic product sales and 25% from brand product
sales.
The Company’s generic product line is one of the broadest in
the industry, with over 130 products. Watson’s Specialty Products group
markets a line of products that address a number of urologic disorders and its
nephrology group markets a market-leading portfolio of iron replacement
products.
The foundation of Watson's business is an internal R&D
program that leverages the Company's expertise in drug delivery technologies
and product development by taking promising product candidates through clinical
studies. With a robust generic product pipeline, Watson currently has more than
30 abbreviated new drug applications (ANDA) pending approval with the Food and
Drug Administration (FDA). In addition, Watson also has a number of promising
brand products in development, further complementing the Company's growing
urology product portfolio.
Watson Pharmaceuticals has expanded its
access to numerous drug delivery technologies, including solid dosage form,
oral controlled release, transdermal, and oral transmucosal. These
capabilities, combined with seasoned leadership and strategic plans for
long-term growth, are the tools for Watson's creation of consistent cash flow
and an ongoing focus toward enhancing shareholder value.
Latest Watson Pharmaceuticals news
Watson Pharmaceuticals Inc (WPI) more shares bought by Unionbancal Corp. Watson to Host Second Quarter 2008 Earnings Conference Call and Webcast. Watson Pharmaceuticals Inc (WPI) holdings reduced by Advisors Capital Management Llc. Watson Pharmaceuticals Inc (WPI) more shares bought by Exxonmobil Investment Management Inc. West MixJect System Selected By Watson For Use In Treatment Of. Watson Pharmaceuticals Inc (WPI) holdings reduced by Sentinel Trust Co Lba. Watson Pharmaceuticals, Inc. - SWOT Analysis - New Research Report on Companies and Markets. Watson Launches Generic MARINOL(R) Capsules. Watson Pharmaceuticals spent $295,000 on lobbying. Research and Markets: Analysis of Watson Pharmaceuticals Report Out Now. C&L: Una Ryan leaves Avant. ALSO NOTED: Lentigen moves to Gaithersburg; Acorda prices shares; Cytheris releases data; and much more.... ALSO NOTED: Tacere gains Pfizer deal; InterMune reports positive hep C results; ArQule CEO resigns; and much more.... SPOTLIGHT: Bisaro handed reigns at Watson. SPOTLIGHT: Abraxis buys facility. read more
Watson further information:
www.watson.com/ | Watson
news
Page last updated: 05/06/08 |
